{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 456687368
| IUPAC_name = 6-Methoxy-1-phenylpyridazin-1-ium-4-amine; methyl sulfate
| image = Amezinium metilsulfate.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|amezinium-metilsulfate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 30578-37-1
| ATC_prefix = C01
| ATC_suffix = CA25
| ATC_supplemental =  
| PubChem = 71926
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2106667
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64937
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 03NR868ICX
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01304

<!--Chemical data-->
| chemical_formula =  
| C=12 | H=15 | N=3 | O=5 | S=1 
| molecular_weight = 313.32 g/mol
| smiles = COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2.COS(=O)(=O)[O-]
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H11N3O.CH4O4S/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10;1-5-6(2,3)4/h2-8,12H,1H3;1H3,(H,2,3,4)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZEASXVYVFFXULL-UHFFFAOYSA-N
}}

'''Amezinium metilsulfate''' ([[International Nonproprietary Name|INN]], trade name '''Regulton''') is a [[sympathomimetic]] drug used for the treatment of low [[blood pressure]]. It has multiple mechanisms, including stimulation of [[alpha receptor|alpha]] and [[beta-1 receptor]]s and inhibition of [[noradrenaline]] and [[tyramine]] uptake.<ref>{{Cite journal 
| last1 = Araújo 
| first1 = D 
| last2 = Caramona 
| first2 = MM 
| last3 = Osswald 
| first3 = W 
| title = On the mechanism of action of amezinium methylsulphate on the dog saphenous vein 
| journal = European Journal of Pharmacology 
| volume = 90 
| issue = 2–3 
| pages = 203–14 
| year = 1983 
| pmid = 6873182
| doi=10.1016/0014-2999(83)90238-8
}}</ref><ref>{{Cite journal 
| last1 = Lenke | first1 = D. 
| last2 = Gries | first2 = J. 
| last3 = Kretzschmar | first3 = R. 
| title = Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action 
| journal = Arzneimittel-Forschung 
| volume = 31 
| issue = 9a 
| pages = 1558–1565 
| year = 1981 
| pmid = 7197970
}}</ref>

==References==
{{reflist}}

{{Cardiac stimulants excluding cardiac glycosides}}

[[Category:Pyridazines]]


{{cardiovascular-drug-stub}}